Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25766831 | 0.87 | TSHR (0.37) | BTN3A1LMNACA12CA1CA2 | |
| SCHEMBL15682800 | 0.81 | BTN3A1 (0.36) | BTN3A1LMNAFBP1TSHR | |
| SCHEMBL15682873 | 0.81 | BTN3A1 (0.36) | BTN3A1LMNAFBP1TSHR | |
| SCHEMBL17525234 | 0.81 | BTN3A1 (0.36) | BTN3A1LMNAFBP1TSHR | |
| SCHEMBL24211997 | 0.80 | BTN3A1 (0.37) | BTN3A1FBP1ALDH1A1 | |
| SCHEMBL18512735 | 0.78 | BTN3A1 (0.33) | BTN3A1CA12CA1CA2CA9 | |
| SCHEMBL19235581 | 0.77 | BTN3A1 (0.38) | BTN3A1LMNAFBP1TSHR | |
| SCHEMBL18512898 | 0.75 | BTN3A1 (0.37) | BTN3A1CA12CA1CA2CA9 | |
| SCHEMBL20181441 | 0.73 | BTN3A1 (0.36) | BTN3A1LMNACA12CA1CA2 | |
| SCHEMBL17527838 | 0.73 | BTN3A1 (0.56) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ADH1A, ADH1C, ADH5 | BTN3A1 2751/4885LMNA 4632/4885CA12 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.